{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Health Affairs This Week","title":"A Peek Behind the Medicare Drug Price Negotiation Curtain","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/46971e94\"></iframe>","width":"100%","height":180,"duration":711,"description":"Health Affairs' Jeff Byers welcomes Senior Editor Ellen Bayer to the program to discuss the ongoing progress of the Inflation Reduction Act of 2022, how it's being implemented, and how we can best evaluate the Medicare Drug Price Negotiation Program.\nHealth Affairs will be hosting a virtual Journal Club event on Tuesday, August 27, entitled \"Coverage of Anti-Obesity Medicines Could Increase Medicare Spending By Billions\" featuring author Benedic Ippolito discussing his recent paper on the topic.\nThis event is exclusive to our Health Affairs Insiders. \nIf you have yet to become an Insider, sign up today to stay up-to-date on what health care experts are thinking and talking about.\nRelated Articles:\nIs It Working? Evaluating The First Round Of Medicare Drug Price Negotiations (Health Affairs)\nFACT SHEET: Biden-⁠Harris Administration Announces New, Lower Prices for First Ten Drugs Selected for Medicare Price Negotiation to Lower Costs for Millions of Americans\nThe First-Ever Government Negotiation Process For Drugs Has Finished, But The Politics Are Ongoing (Health Affairs Forefront)\nFAQs about the Inflation Reduction Act’s Medicare Drug Price Negotiation Program (KFF)\nExplaining the Prescription Drug Provisions in the Inflation Reduction Act (KFF)","thumbnail_url":"https://img.transistorcdn.com/1yTEmrg3NcfwPvygDcOosqdCKJnotdzHk5P0Oq8y-us/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzE2NjA3LzE2MDY4/MzkyNjUtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}